Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC8 | Q9BY41 | 3/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.71 |
| ▸ | MAPT | P10636 | 2/20 | 0.71 |
| ▸ | GAA | P10253 | 1/20 | 0.71 |
| ▸ | RAB9A | P51151 | 8/20 | 0.67 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.67 |
| ▸ | NFKB1 | P19838 | 3/20 | 0.67 |
| ▸ | NFKB2 | Q00653 | 3/20 | 0.67 |
| ▸ | RELA | Q04206 | 3/20 | 0.67 |
| ▸ | MGAM | O43451 | 1/20 | 0.63 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.63 |
| ▸ | NPC1 | O15118 | 7/20 | 0.59 |
| ▸ | TP53 | P04637 | 3/20 | 0.59 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.59 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.59 |
| ▸ | TSHR | P16473 | 1/20 | 0.59 |
| ▸ | HPGD | P15428 | 3/20 | 0.58 |
| ▸ | MEN1 | O00255 | 3/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18530693 | 1.00 | HDAC8 (1.00) | HDAC8ALDH1A1MAPTGAARAB9A | |
| SCHEMBL13381527 | 0.86 | HDAC8 (0.76) | HDAC8ALDH1A1MAPTGAARAB9A | |
| Imidazole SCHEMBL11403562 | 0.84 | HDAC8 (0.70) | HDAC8ALDH1A1MAPTGAARAB9A | |
| SCHEMBL2551255 | 0.83 | ALDH1A1 (1.00) | HDAC8ALDH1A1MAPTGAARAB9A | |
| SCHEMBL9839810 | 0.83 | HDAC8 (0.71) | HDAC8ALDH1A1MAPTGAARAB9A | |
| Water SCHEMBL10373155 | 0.81 | ALDH1A1 (0.96) | HDAC8ALDH1A1MAPTGAARAB9A | |
| SCHEMBL1131467 | 0.80 | SMN1; SMN2 (1.00) | HDAC8ALDH1A1MAPTGAARAB9A | |
| SCHEMBL29291517 | 0.80 | HDAC8 (0.67) | HDAC8ALDH1A1MAPTGAARAB9A | |
| SCHEMBL28483264 | 0.80 | HDAC8 (0.67) | HDAC8ALDH1A1MAPTGAARAB9A | |
| SCHEMBL1343443 | 0.79 | CNR2 (0.78) | HDAC8ALDH1A1MAPTGAARAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111875582-B | Quinoline hydroxamic acid derivative and preparation method and application thereof | 深圳贝瑞生物医药科技有限公司 | 2021-06-01 | — | — | CN | claimed |
| CN-111875582-A | Quinoline hydroxamic acid derivative and preparation method and application thereof | 清华大学深圳国际研究生院 | 2020-11-03 | — | — | CN | claimed |
| CN-116478130-B | N-hydroxyquinoline carboxamide compounds and uses thereof | 深圳默元生物科技有限公司 | 2025-05-30 | — | — | CN | disclosed |
| CN-116478130-B | N-hydroxyquinoline carboxamide compounds and uses thereof | 深圳默元生物科技有限公司 | 2025-05-30 | — | — | CN | disclosed |
| CN-116478130-B | N-hydroxyquinoline carboxamide compounds and uses thereof | 深圳默元生物科技有限公司 | 2025-05-30 | — | — | CN | disclosed |
| CN-116284160-B | Hexanuclear rare earth-transition complex and preparation method thereof | 南通大学 | 2024-10-15 | — | — | CN | disclosed |
| CN-117024484-A | Metal crown ether type double-layer rare earth-transition complex and preparation method thereof | 南通大学 | 2023-11-10 | — | — | CN | disclosed |
| WO-2023138674-A1 | N-HYDROXYQUINOLINE CARBOXAMIDE COMPOUND AND USE THEREOF | 默达药物（香港）有限公司 | 2023-07-27 | — | — | WO | disclosed |
| WO-2023138674-A1 | N-HYDROXYQUINOLINE CARBOXAMIDE COMPOUND AND USE THEREOF | 默达药物（香港）有限公司 | 2023-07-27 | — | — | WO | disclosed |
| WO-2023138674-A1 | N-HYDROXYQUINOLINE CARBOXAMIDE COMPOUND AND USE THEREOF | 默达药物（香港）有限公司 | 2023-07-27 | — | — | WO | disclosed |
| CN-116478130-A | N-hydroxyquinoline carboxamide compounds and uses thereof | 深圳默元生物科技有限公司 | 2023-07-25 | — | — | CN | disclosed |
| US-20020132826-A1 | Preparation and use of ortho-sulfonamido bicyclic heteroaryl hydroxamic acids as matrix metalloproteinase and tace inhibitors | WYETH HOLDINGS CORPORATION | 2002-09-19 | — | — | US | disclosed |
| US-20010046989-A1 | Preparation and use of ortho-sulfonamido bicyclic heteroaryl hydroxamic acids as matrix metalloproteinase and TACE inhibitors | WYETH HOLDINGS CORPORATION | 2001-11-29 | — | — | US | disclosed |
| US-20010025047-A1 | Preparation and use of ortho-sulfonamido bicyclic heteroaryl hydroxamic acids as matrix metalloproteinase and tace inhibitors | WYETH HOLDINGS CORPORATION | 2001-09-27 | — | — | US | disclosed |
| US-6228869-B1 | ANTITUMOR, ANTIMETASTASIS, ANTIARTHRITIC, AND WOUND HEALING AGENTS; QUINOLINE AND ISOQUINOLINE DERIVATIVES | AMERICAN CYANAMID COMPANY | 2001-05-08 | — | — | US | disclosed |
| CN-1280568-A | Preparation and use of ortho-sulfonamido bicyclic heteroaryl hydroxamic acids as matrix metalloproteinase and TACE inhibitors | AMERICAN CYANAMID CO (US) | 2001-01-17 | — | — | CN | disclosed |
| EP-1021413-A1 | THE PREPARATION AND USE OF ORTHO-SULFONAMIDO BICYCLIC HETEROARYL HYDROXAMIC ACIDS AS MATRIX METALLOPROTEINASE AND TACE INHIBITORS | American Cyanamid Company (US) | 2000-07-26 | — | — | EP | disclosed |
| WO-1999018076-A1 | THE PREPARATION AND USE OF ORTHO-SULFONAMIDO BICYCLIC HETEROARYL HYDROXAMIC ACIDS AS MATRIX METALLOPROTEINASE AND TACE INHIBITORS | AMERICAN CYANAMID COMPANY (US) | 1999-04-15 | — | — | WO | disclosed |
| WO-1998016514-A1 | ORTHO-SULFONAMIDO BICYCLIC HETEROARYL HYDROXAMIC ACIDS AS MATRIX METALLOPROTEINASE AND TACE INHIBITORS | AMERICAN CYANAMID COMPANY (US) | 1998-04-23 | — | — | WO | disclosed |
| US-5294717-A | Bifunctional chelating agents, their chelates and process of preparation | THEODOROPULOS SPYROS (US) | 1994-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020132826-A1 | Preparation and use of ortho-sulfonamido bicyclic heteroaryl hydroxamic acids as matrix metalloproteinase and tace inhibitors | MSR1, TIMP3, OGFR | HDAC8 483/4885ALDH1A1 4301/4885MAPT 3867/4885 |
| US-20010025047-A1 | Preparation and use of ortho-sulfonamido bicyclic heteroaryl hydroxamic acids as matrix metalloproteinase and tace inhibitors | MSR1, TIMP3, TGFBR2 | HDAC8 495/4885ALDH1A1 4273/4885MAPT 4095/4885 |
| US-20010046989-A1 | Preparation and use of ortho-sulfonamido bicyclic heteroaryl hydroxamic acids as matrix metalloproteinase and TACE inhibitors | MSR1, TIMP3, TGFBR2 | HDAC8 438/4885ALDH1A1 4181/4885MAPT 4061/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.